Direk LimmathurotsakulSimon G.P. FunnellAlfredo G. TorresLisa A. MoriciPaul J. BrettSusanna DunachieTimothy AtkinsDaniel M. AltmannGregory BancroftSharon J. PeacockMahidol UniversityPublic Health EnglandUT Medical Branch at GalvestonTulane University School of MedicineUniversity of South AlabamaUniversity of OxfordDefence Science and Technology LaboratoryImperial College LondonLondon School of Hygiene & Tropical MedicineUniversity of Cambridge2018-11-232018-11-232015-06-01Emerging Infectious Diseases. Vol.21, No.6 (2015), e1-e710806059108060402-s2.0-84981749578https://repository.li.mahidol.ac.th/handle/123456789/36429© 2015, Marmara University. All rights reserved. Several candidates for a vaccine against Burkholderia pseudomallei, the causal bacterium of melioidosis, have been developed, and a rational approach is now needed to select and advance candidates for testing in relevant nonhuman primate models and in human clinical trials. Development of such a vaccine was the topic of a meeting in the United Kingdom in March 2014 attended by international candidate vaccine developers, researchers, and government health officials. The focus of the meeting was advancement of vaccines for prevention of natural infection, rather than for protection from the organism’s known potential for use as a biological weapon. A direct comparison of candidate vaccines in well-characterized mouse models was proposed. Knowledge gaps requiring further research were identified. Recommendations were made to accelerate the development of an effective vaccine against melioidosis.Mahidol UniversityMedicineArticleSCOPUS10.3201/eid2106.141480